Undisclosed CTLA-4×TIGIT BsAb / BitD - LARVOL DELTA

Anti-human CTLA-4×TIGIT bispecific antibody: A novel immunotherapy specifically targeting tumor-infiltrating FOXP3+ regulatory T cells (AACR 2026) - "Current anti-Treg therapies, such as the anti-CTLA-4 monoclonal antibody ipilimumab, show significant clinical efficacy but often induce severe systemic toxicity due to broad depletion of peripheral Tregs... These findings indicate that the anti-human CTLA-4×TIGIT BsAbs specifically targets tumor-infiltrating Tregs and represents a promising strategy for maximizing specificity while minimizing systemic effects."

Bispecific • IO biomarker • Cervical Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8 • CTLA4 • FOXP3 • TIGIT

A first-in-class CTLA-4×TIGIT BsAb selectively targets tumor-associated Treg cells to improve the safety profile of CTLA-4 targeting therapy (AACR 2025) - "In vitro, we established CHO-K1-CTLA4 cells representing peripheral Tregs and CHO-K1-CTLA-4/TIGIT cells representing tumor-associated Tregs...In the GLP toxicity study, the CTLA-4×TIGIT BsAb exhibited a more favorable safety profile than CTLA-4 mAbs such as ipilimumab and tremelimumab. Our preclinical study thoroughly evaluated the in vitro and in vivo activity of the CTLA-4×TIGIT BsAb and demonstrated its mechanism of action in targeting tumor-associated Tregs, which confirms that the specificity towards tumor-associated Treg cells preserves efficient anti-tumor activity while enhancing the safety profile of CTLA-4 targeting therapy. Our preclinical study thoroughly evaluated the in vitro and in vivo activity of the CTLA-4×TIGIT BsAb and demonstrated its mechanism of action in targeting tumor-associated Tregs, which confirms that the specificity towards tumor-associated Treg cells preserves efficient anti-tumor activity while enhancing the safety profile..."

Clinical • IO biomarker • Late-breaking abstract • Oncology • CD80 • TIGIT